Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2

BACKGROUND: The HER2-inhibiting antibody trastuzumab, in combination with chemotherapy, significantly improves survival of women with resected, HER2-overexpressing breast cancers, but is associated with toxicities including a risk of cardiomyopathy. Additionally, the beneficial effect of trastuzumab...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Morse, Michael A, Hobeika, Amy, Osada, Takuya, Niedzwiecki, Donna, Marcom, Paul Kelly, Blackwell, Kimberly L, Anders, Carey, Devi, Gayathri R, Lyerly, H Kim, Clay, Timothy M
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2007
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2042490/
https://ncbi.nlm.nih.gov/pubmed/17822557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-5-42
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares